Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Chemo & Immunotherapy in Primary CNS Lymphoma
NCT00098774Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2004
- Primary completion
- Jan 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in primary central nervous system lymphoma (PCNSL), sponsored by Cancer and Leukemia Group B. Started Oct 2004; status: completed.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00098774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098774.